Does IMATINIB Cause Bladder transitional cell carcinoma? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Bladder transitional cell carcinoma have been filed in association with IMATINIB (Imatinib). This represents 0.0% of all adverse event reports for IMATINIB.
8
Reports of Bladder transitional cell carcinoma with IMATINIB
0.0%
of all IMATINIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From IMATINIB?
Of the 8 reports, 2 (25.0%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IMATINIB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does IMATINIB Cause?
Death (9,708)
Drug ineffective (2,628)
Nausea (2,379)
Diarrhoea (2,203)
Fatigue (1,810)
Malignant neoplasm progression (1,716)
Vomiting (1,599)
Malaise (1,361)
Drug intolerance (1,354)
Drug resistance (1,293)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which IMATINIB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
IMATINIB vs IMBRUVICA
IMATINIB vs IMDEVIMAB
IMATINIB vs IMEGLIMIN
IMATINIB vs IMETELSTAT
IMATINIB vs IMIDAPRIL